Glucose meter development gets €50,000 from Horizon 2020
A Swedish company has fought off stiff competition to receive €50,000 in funding from Horizon 2020.
Senzime will use the money to undertake a feasibility study of a body and near-patient, specific, and accurate glucose meters that can be installed in intensive care, providing a solution to current unmet clinical needs. The feasibility study is expected to take six months and will be completed during the second half of 2015. With good outcomes, this could result in significant funding for the company’s future clinical development of the concept and possible further applications for EU funding for the continued clinical documentation.
Lena Söderström, chief executive of Senzime AB, said: “Research in recent years has shown that if you can maintain normal blood glucose levels during and after operation of critically ill patients in intensive care units, whether they are diabetic or not, there is reduced morbidity and mortality among these patients. We see the Horizon 2020 grant as further confirmation that the measurement of glucose in the blood is important and that Senzime is a leading player in the field.”
Senzime is based in Uppsala, Sweden.
